Arcturus Therapeutics price target lowered to $20 from $42 at Wells Fargo

Wells Fargo lowered the firm’s price target on Arcturus Therapeutics (ARCT) to $20 from $42 and keeps an Overweight rating on the shares. The firm Phase 2 data suggests establishing efficacy of inhaled mRNA may take more effort than expected. Wells does think mucus reduction data are intriguing, especially with anatomical consistency.